Natural History of ABCA4-Related Retinopathies
Natural History of ABCA4-Related Retinopathies
批准号:
10706127
负责人:
Brian Brooks
金额:
$68.61万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AddressAgeBiological AssayBiopsyBlood specimenCOVID-19 pandemicCell Differentiation processCellsCellular biologyChildClinicClinical ResearchClinical TrialsConsentDNADataData AnalysesDiagnostic ImagingDiseaseDisease ProgressionDisease modelDoseElectrophysiology (science)ElectroretinographyEligibility DeterminationEnrollmentEvaluationEyeFDA approvedFamilyFibroblastsFive-Year PlansFlecksFollow-Up StudiesFormulationFutureGenerationsGenotypeGoalsImageIn VitroInstitutional Review BoardsInvestigationMeasuresMedicalMedical GeneticsMedical RecordsMetforminMolecularMonitorNatural HistoryNeural RetinaNuclearOptical Coherence TomographyOral cavityOutcomeOutcome MeasureOutcome StudyParticipantPathogenesisPatientsPerimetryPhase II Clinical TrialsPhenotypePlant RootsPlasmaPopulation StudyProtocols documentationPsychophysiologyQuestionnairesRecording of previous eventsResearch PersonnelRetinaRetinal DiseasesSamplingScanningSerumSkinStandardizationStructure of retinal pigment epitheliumTechniquesTherapeuticThinnessTimeUnited States National Institutes of HealthVisionVision TestsVisitWorkbaseclinical outcome measurescohortdeep learningefficacy testingfollow-upgenetic testinghigh-throughput drug screeninginduced pluripotent stem cellmembrane-associated placental tissue protein 1novelopen labelophthalmic examinationprimary outcomerecruitrepositorysecondary outcometime usetreatment trial
中文摘要
1. ABCA4视网膜病变自然史研究
英文摘要
1. ABCA4 Retinopathy Natural History Study
In the ABCA4 natural history study, participants will be followed for five years. Participants will be recruited through other pre-existing NIH protocols, such as the NEI Evaluation and Treatment Trial (08-EI-0169), the NEI Screening Protocol (08-EI-0102), and the National Ophthalmic Disease Genotyping and Phenotyping Network, Phase II protocol (eyeGENE II, 10-EI-N164), or through referral from an outside clinician after a review of pertinent medical records and genetic testing. All participants will undergo a standardized medical/ophthalmic history and a complete baseline eye examination, including non-invasive electrophysiology (e.g., electroretinography), psychophysiology (e.g., microperimetry, static perimetry), and diagnostic imaging examinations (e.g., optical coherence tomography, OCT).
Participants will be examined three times over the course of the first year (i.e., baseline, month 6, and month 12). After the first year, they will return to the NEI clinic on an annual basis for the next four years. This study will require a minimum of seven visits. Participants may be seen at more frequent intervals at the investigator's discretion, depending on the clinical and research situation. Participants will be required to submit a blood sample as part of the study for DNA and serum banking, and they will have the option to provide a 3 mm punch skin biopsy to develop in vitro disease models and facilitate cell biology investigations.
The primary outcome for this study is the establishment of a cohort of participants with ABCA4-related retinopathies, and the secondary outcome is the creation of a repository of plasma, DNA, and skin fibroblast samples from the accrued cohort of ABCA4-related retinopathy participants. Exploratory outcomes for this study include: 1) the formulation of clinical outcome measures for future studies and 2) the acquisition and preliminary analysis of data that may advance our understanding of genotype-phenotype correlations in ABCA4-related retinopathies. Potential exploratory outcomes include: 1) the generation of induced pluripotent stem cells (iPSCs) from the skin fibroblast samples, 2) the differentiation of the generated iPSC into RPE and/or neural retinal cells, and 3) the use of the participant-specific RPE and/or neural retinal cells to perform high throughput (HTP) drug screens to identify novel potentially therapeutic compounds. Functional measures such as retinal sensitivity as measured by MP1 and structural changes on OCT are being specifically addressed. Additionally, we are analyzing change over time using autofluorescence images and working on novel analysis techniques looking at the progression/natural history of flecks.
A number of enrolled participants have completed the originally planned five-year natural history and their period of follow-up has been extended. A selected battery of assays with high data yield will be performed on these patients. Furthermore, OCT parameters have been established to be used as outcome measure in future clinical trials.
We have used a deep learning approach to analyze the OCT scans of 132 eyes (66 patients) from this natural history study and correlate our findings with genotype. We found a progression rate of 0.09mm/y (square root transform of are of EZ band loss) and show that outer nuclear layer thinning extends beyond the aera of EZ loss. We have correlated this genotypic information from these patients.
2. Metformin administration to slow down progression of ABCA4 Retinopathy
Based on currently available data from the above population study, an open label phase II clinical trial has received FDA and NIH IRB approval to proceed and was started in November 2020 (20-EI-0163.) The goal of the trial is to test the efficacy of the FDA-approved compound metformin in slowing the rate of disease progression.
Participants screened under the natural history study protocol will have a medical and family history. They will complete a questionnaire about their vision and daily activities. They will undergo a physical exam and extensive eye exam and vision testing. A blood sample may be drawn. Participants will take metformin by mouth for 24 months and will be monitored with study visits every 6 months. Study follow-up will continue for an additional 12 months. Participants will receive an immediate release formulation of metformin of 500mg daily at study entry. This dose will be titrated up weekly in 500mg increments to reach 2000mg daily maximum. Thereafter, they will switch to an extended-release formulation (1000mg twice a day by mouth). If 2000mg/day is not tolerated, the dose could be reduced to a minimum of 1000mg/day. Since metformin extended release is not FDA-approved for children under the age of 17, participants under 17 will remain on the immediate release formulation.
Because of the Covid-19 pandemic, work in the clinic has been slower than usual for the past year but has started to return to normal in recent weeks.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Genetics of Uveal Coloboma
-
批准号:8737645
-
项目类别:
-
资助金额:$165.71万
-
财政年份:--
-
负责人:Brian Brooks
-
依托单位:
Ophthalmic Genetics Fellowship
-
批准号:8737702
-
项目类别:
-
资助金额:$50.82万
-
财政年份:--
-
负责人:Brian Brooks
-
依托单位:
The Genetics of Uveal Coloboma
-
批准号:8938329
-
项目类别:
-
资助金额:$158.08万
-
财政年份:--
-
负责人:Brian Brooks
-
依托单位:
Ophthalmic Genetics Fellowship
-
批准号:9362459
-
项目类别:
-
资助金额:$71.9万
-
财政年份:--
-
负责人:Brian Brooks
-
依托单位:
Ophthalmic Genetics Fellowship
-
批准号:7970287
-
项目类别:
-
资助金额:$12.25万
-
财政年份:--
-
负责人:Brian Brooks
-
依托单位:
Natural History of ABCA4-Related Retinopathies
-
批准号:10266904
-
项目类别:
-
资助金额:$20.18万
-
财政年份:--
-
负责人:Brian Brooks
-
依托单位:
Natural History of ABCA4-Related Retinopathies
-
批准号:10930525
-
项目类别:
-
资助金额:$75.44万
-
财政年份:--
-
负责人:Brian Brooks
-
依托单位:
Ophthalmic Genetics Fellowship
-
批准号:8149725
-
项目类别:
-
资助金额:$12.17万
-
财政年份:--
-
负责人:Brian Brooks
-
依托单位:
Pre-clinical and clinical studies of NTBC and other compounds as potential treatments for albinism
-
批准号:10706112
-
项目类别:
-
资助金额:$151.93万
-
财政年份:--
-
负责人:Brian Brooks
-
依托单位:
CRX-mediated Leber Congenital Amaurosis
-
批准号:7968426
-
项目类别:
-
资助金额:$39.81万
-
财政年份:--
-
负责人:Brian Brooks
-
依托单位:
Generation of Induced Pluripotent Stem (iPS) Cell Lines from Somatic Cells of Participants with Eye Diseases and from Somatic Cells of Matched Controls
-
批准号:8938372
-
项目类别:
-
资助金额:$14.55万
-
财政年份:--
-
负责人:Brian Brooks
-
依托单位:
The Genetics of Uveal Coloboma
-
批准号:10930511
-
项目类别:
-
资助金额:$167.05万
-
财政年份:--
-
负责人:Brian Brooks
-
依托单位:
Pre-clinical and clinical studies of NTBC and other compounds as potential treatments for albinism
-
批准号:10930512
-
项目类别:
-
资助金额:$103.54万
-
财政年份:--
-
负责人:Brian Brooks
-
依托单位:
The Genetics of Uveal Coloboma
-
批准号:8556845
-
项目类别:
-
资助金额:$189.94万
-
财政年份:--
-
负责人:Brian Brooks
-
依托单位:
Pre-clinical and clinical studies of NTBC as a potential treatment for albinism
-
批准号:8938330
-
项目类别:
-
资助金额:$46.07万
-
财政年份:--
-
负责人:Brian Brooks
-
依托单位:
Pre-clinical and clinical studies of NTBC as a potential treatment for albinism
-
批准号:9155583
-
项目类别:
-
资助金额:$41.14万
-
财政年份:--
-
负责人:Brian Brooks
-
依托单位:
Natural History of ABCA4-Related Retinopathies
-
批准号:9555704
-
项目类别:
-
资助金额:$1.31万
-
财政年份:--
-
负责人:Brian Brooks
-
依托单位:
Pre-clinical and clinical studies of NTBC and other compounds as potential treatments for albinism
-
批准号:9555689
-
项目类别:
-
资助金额:$50.93万
-
财政年份:--
-
负责人:Brian Brooks
-
依托单位:
Natural History of Spinocerebellar Ataxia Type 7 (SCA7)
-
批准号:10706134
-
项目类别:
-
资助金额:$26.61万
-
财政年份:--
-
负责人:Brian Brooks
-
依托单位:
Pre-clinical and clinical studies of NTBC and other compounds as potential treatments for albinism
-
批准号:10266890
-
项目类别:
-
资助金额:$102.37万
-
财政年份:--
-
负责人:Brian Brooks
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: